Compare Nano Dimension Ltd - ADR (NNDM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Regeneron Pharmaceuticals Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.51 (market cap $327.47M), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 254.8× Nano Dimension Ltd - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| NNDM | REGN | |
|---|---|---|
Market Cap | $327.47M | $83.43B |
Sector | Technology | Health |
52-Week High | $2.14 | $852.03 |
52-Week Low | $1.21 | $555.51 |
Enterprise Value | -$77.38M | $78.14B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, amid a bearish technical signal and negative cash flow. The company reported a net loss of $293.30M on $102.44M revenue in 2025, with a negative net income margin of 135.18%. Recent news highlights board changes, cost-saving initiatives, and a planned sale of MarkForged to Stratasys, aimed at reducing cash burn.
The outlook remains challenged by persistent losses and cash burn, though strategic divestitures may improve liquidity. Key risks include execution of turnaround plans and competitive pressures. Analyst sentiment is cautious given the financial performance and ongoing corporate restructuring.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
